08:15 AM EDT, 06/24/2024 (MT Newswires) -- Regulus Therapeutics ( RGLS ) said Monday that results from the third cohort of patients in its phase 1b study showed that its investigational drug RGLS8429 was "well-tolerated with no safety concerns."

The investigational drug is being evaluated in adults with autosomal dominant polycystic kidney disease, or ADPKD. Enrolment is ongoing for the fourth cohort, according to Regulus.

In the third cohort, 16 patients were randomized to receive either 3 mg/kg of RGLS8429 or placebo every other week for three months, the company said, adding there was continued evidence of a mechanistic dose response.

Regulus Therapeutics ( RGLS ) shares were up more than 26% in recent premarket activity.

Price: 3.1700, Change: +0.66, Percent Change: +26.29